This site is intended for health professionals only!

Published on 21 October 2014

Share this story:

Bayer’s Adempas® receives ‘Highly Commended’ honour at 2014 Prix Galien Awards

Bayer HealthCare is delighted to announce that the innovative drug, Adempas, has received a Prix Galien Award – a High Commendation at the 2014 ceremony at The House of Commons. The bi-annual awards are designed to recognise the significant contribution the pharmaceutical industry makes in clinical research and drug development.

Bayer HealthCare is delighted to announce that the innovative drug, Adempas, has received a Prix Galien Award – a High Commendation at the 2014 ceremony at The House of Commons. The bi-annual awards are designed to recognise the significant contribution the pharmaceutical industry makes in clinical research and drug development.

This year’s judging panel commended the ability of Adempas to stimulate the soluble guanylate cyclase (SGC) enzyme, an important regulator in the cardiovascular system and recognising its impact in patients with CTEPH and pulmonary arterial hypertension (PAH).

Chairman of the judging panel, Professor Sir Michael Rawlins, said: “The Prix Galien is about recognising the contribution that new medicines make to the lives of people with life-threatening conditions. We had an outstanding group of contenders this year – with a total of 14 shortlisted products across both the Innovative Product and Orphan Drug awards.”

Bayer UK Managing Director, Dr Alexander Moscho, said: “Bayer HealthCare is proud to participate in these awards and to be recognised once again for the company’s contribution to the development of life changing medicines, having been awarded the Prix Galien for Innovation in 2010 for Xarelto (rivaroxaban) and again shortlisted for Xarelto at the last Awards in 2012.

Dan Coombes, Business Unit Head for General Medicines at Bayer HealthCare, added: “The recognition at Prix Galien 2014 of Bayer’s ongoing and relentless efforts to push the boundaries of drug development and not shy away from those ‘hard to treat’ conditions, such as CTEPH, is further fuel to our work. We look forward to the future and to potentially joining other trailblazers in our industry at the 2016 Prix Galien Awards.”

The 2014 ceremony was hosted by former shadow Minister for Health, the Rt Hon Sir Kevin Barron, MP, currently Chair of the All Party Pharmacy Group and co?Chair of the Associate Parliamentary Health Group. Sir Kevin commented:
It’s a privilege to be here to applaud the labours of the scientists, clinicians and healthcare leaders who continue to contribute enormously to the ongoing battle against human disease. The pharmaceutical industry’s contribution to the UK economy is significant. The sector’s continued commitment to improving health outcomes and curbing disease across the full gamut of chronic, long-term and rare conditions is extraordinary.”



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine